Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

Inclusion Criteria:

• Be willing and able to adhere to the study procedures, including all requirements atthe study center, and return for the follow-up visit.

• Have a medically confirmed diagnosis of classic CAH due to 21-hydroxylasedeficiency.

• Be on a stable steroid regimen.

• Have elevated androgen levels.

• Participants of childbearing potential must be abstinent or agree to use appropriatebirth control during the study.

Exclusion Criteria:

• Have a diagnosis of any of the other forms of classic CAH.

• Have a history of bilateral adrenalectomy, hypopituitarism, or other conditionrequiring chronic glucocorticoid therapy.

• Have a clinically significant unstable medical condition or chronic disease otherthan CAH.

• Have a history of cancer unless considered to be cured.

• Have a known history of clinically significant arrhythmia or abnormalities onelectrocardiogram (ECG).

• Have a known hypersensitivity to any corticotropin-releasing hormone antagonist.

• Have received an investigational drug within 30 days before initial screening orplan to use an investigational drug (other than the study drug) during the study.

• Have current substance dependence or substance (drug) or alcohol abuse.

• Have had a significant blood loss or donated blood or blood products within 8 weeksprior to the study.